Literature DB >> 11823689

Malignant fibrous histiocytoma: a retrospective study of 109 cases.

Abdelaziz Belal1, Alaa Kandil, Ayman Allam, Yasser Khafaga, Gamal El-Husseiny, Ashraf El-Enbaby, Mohamed Memon, Derek Younge, Paul Moreau, Alan Gray, Henrik Schultz.   

Abstract

The purpose of this report is to assess the prognostic factors that could influence management and clinical outcome of malignant fibrous histiocytoma (MFH) of soft tissues. Between 1975 and 1998, 109 patients diagnosed with MFH of the soft tissues, seen at King Faisal Specialist Hospital and Research Center, have been reviewed. Of the 109 patients, 75 were men and 34 were women. The median age at presentation was 48 years (range: 3-94). Seven patients (6%) had regional nodal disease and 10 other patients (9%) with distant metastases were excluded from survival analysis. The remaining 92 patients had localized disease and had surgery as the primary treatment modality with or without radiotherapy and/or chemotherapy. Extremities were the most common location (58%). Tumors less than 5 cm represented 32%, whereas 68% had tumors 5 cm or more. Low-grade tumors constituted 46%, and the remaining 54% were high grade. Thirty-seven percent of patients had positive surgical margins histologically after complete gross resection. The 5- and 10-year relapse-free survival (RFS) rates were 39% and 36%, respectively. Isolated local recurrence occurred in 20 patients (22%), isolated metastatic disease without local recurrence in 9 patients (10%), and combined local and metastatic disease occurred in 20 patients (22%). The overall 5- and 10-year overall survival (OS) rates were 50% and 43%, respectively. On multivariate analysis, tumor size and radiation dose were significant factors for RFS (p = 0.04 and 0.0005, respectively). In terms of OS, size, histologic grade, and surgical margins were significant factors on multivariate analysis (p = 0.001. 0.006, and 0.0001, respectively). Complete surgical resection at the time of primary tumor presentation is likely to afford the best chance for RFS and OS. Radiation therapy plays an important role, in combination with surgery for better local control, particularly in high-grade lesions, and in cases with positive surgical margins after wide complete gross excision. The role of adjuvant chemotherapy remains investigational.

Entities:  

Mesh:

Year:  2002        PMID: 11823689     DOI: 10.1097/00000421-200202000-00003

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  30 in total

1.  Can pancreaticoduodenectomy be used to palliate selective metastatic malignancies? Case report of malignant fibrous histiocytoma.

Authors:  Mindy M Ho; Thomas J Howard; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

2.  A case of primary malignant fibrous histiocytoma of the pancreas: CT and MRI findings.

Authors:  Ri-Sheng Yu; Jia-Wei Wang; Ying Chen; Wen-Hong Ding; Xiu-Fang Xu; Li-Rong Chen
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

3.  Primary malignant fibrous histiocytoma of the chest wall misdiagnosed as traumatic hemothorax.

Authors:  Ki-Eun Hwang; June-Seong Hwang; Kyung-Min Kim; Jae-Wan Jung; Su-Jin Oh; Eun-Kyoung Kim; Dae-Woon Ryu; Keum-Ha Choi; Eun-Taik Jeong; Hak-Ryul Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-06-28

4.  Clinical report on transarterial neoadjuvant chemotherapy of malignant fibrous histiocytoma in soft tissue.

Authors:  Jun Guo; Qiu Cui; Cheng Liu; Jiahong Sui; Ning Jiang; Ju Zhou; Dingfeng Li; Yanjun Zeng
Journal:  Clin Transl Oncol       Date:  2012-09-14       Impact factor: 3.405

5.  Imaging features of primary and metastatic extremity synovial sarcoma: a single institute experience of 78 patients.

Authors:  A D Baheti; S H Tirumani; R Sewatkar; A B Shinagare; J L Hornick; N H Ramaiya; J P Jagannathan
Journal:  Br J Radiol       Date:  2014-11-28       Impact factor: 3.039

6.  Malignant fibrous histiocytoma of chest wall.

Authors:  Jin-Kyung An; Ki Keun Oh
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

7.  MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities -- an analysis of 140 patients.

Authors:  Marcus Lehnhardt; Adrien Daigeler; Heinz H Homann; Vanessa Schwaiberger; Ole Goertz; Cornelius Kuhnen; Hans U Steinau
Journal:  Langenbecks Arch Surg       Date:  2008-06-27       Impact factor: 3.445

8.  Giant cell malignant fibrous histiocytoma of the breast: a case report.

Authors:  Se Jeong Oh; Kyoung Mee Kim; Tae Ho Hong; Woo Chan Park; Jeong Soo Kim; Sang Seol Jung
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

9.  Primary malignant fibrous histiocytoma of the pleura.

Authors:  Kyung-Hwa Cho; Chul Park; Ki-Eun Hwang; Yu-Ri Hwang; Chang-Hwan Seol; Keum-Ha Choi; Mi-Kyung Lee; Soon-Ho Choi; Hak-Ryul Kim; Eun-Taik Jeong
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-05-31

10.  Malignant fibrous histiocytoma--pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study.

Authors:  Adrien Daigeler; Daigeler Adrien; Ludger Klein-Hitpass; Klein-Hitpass Ludger; Ingo Stricker; Stricker Ingo; Oliver Müller; Müller Oliver; Cornelius Kuhnen; Kuhnen Cornelius; Ansgar Michael Chromik; Chromik Ansgar Michael; Lars Steinstraesser; Steinstraesser Lars; Ole Goertz; Goertz Ole; Hans-Ulrich Steinau; Steinau Hans-Ulrich; Marcus Lehnhardt; Lehnhardt Marcus
Journal:  Langenbecks Arch Surg       Date:  2009-01-22       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.